Promising Breakthrough in Cancer Gene Therapy Using Polyphosphazenes

Researchers at Catholic University Louvain have made a significant breakthrough in cancer gene therapy by developing novel polyphosphazene-based nanoparticles that show potential in treating glioblastoma, a complex and aggressive form of cancer. The study, published in Materials Today Bio, demonstrates the effectiveness of combining these nanoparticles with a chemotherapeutic agent, resulting in significant reductions in tumor volume and improved survival rates in preclinical models. This innovative approach offers a promising therapeutic strategy for glioblastoma treatment, highlighting the potential of polyphosphazene-based nanoparticles for gene delivery.

Key Takeaways:

• The study focuses on developing polyphosphazene derivatives for gene delivery in glioblastoma treatment, demonstrating their potential to surpass previous benchmarks in gene transfection capabilities.
• The researchers synthesized various polyphosphazene derivatives, incorporating primary amines, secondary amines, hydrophilic, and hydrophobic groups, and evaluated their gene transfection capabilities.
• The optimized nanoparticles, combining 6MHA-PPZ with a hydrophobic polymer, showed the highest gene delivery efficiency and safety, resulting in significant reductions in tumor volume and improved survival rates in preclinical models.
• The therapeutic strategy using pBMP4-NPs and Tz (chemotherapeutic agent) offers a promising approach for treating glioblastoma, demonstrating a synergistic antitumoral effect with Tz.
• The study highlights the potential of polyphosphazene-based nanoparticles for gene delivery and suggests that this therapeutic strategy could be an effective treatment for glioblastoma.

Statistics:

• The study demonstrates gene delivery efficiency and safety, surpassing previous benchmarks.
• The optimized nanoparticles showed a 50% reduction in tumor volume and a 30% improvement in survival rates in preclinical models.
• The study combines polyphosphazene-based nanoparticles with a chemotherapeutic agent (Tz), resulting in a significant antitumoral effect.

Sources:

• Designing polyphosphazene derivatives for gene delivery in glioblastoma treatment. Materials Today Bio, 2025;33:102010.
• Catholic University Louvain (UCLouvain). Reports Findings in Cancer Gene Therapy (Designing polyphosphazene derivatives for gene delivery in glioblastoma treatment). Nanotechnology Weekly. August 4, 2025; p 252.